| アブストラクト | BACKGROUND: To determine whether the use of disease-modifying antirheumatic drugs (DMARDs) is linked to the risk of COVID-19 among patients with inflammatory rheumatic diseases (IRDs). METHODS: We performed a disproportionality analysis of the World Health Organization pharmacovigilance database between January 1, 2020, and June 10, 2020. The frequency of COVID-19 reports for all DMARD classes identified was compared with that for all other reports for all other drugs and quoted as the reporting odds ratio (ROR) (95% confidence interval [CI]). RESULTS: Among 980,446 individual case-safety reports voluntarily recorded in the database, 398 identified COVID-19 in DMARD-treated patients with IRDs. There were 177 (44.5%) patients with rheumatoid arthritis (RA), 120 (30.1%) with ankylosing spondylitis (AS), 93 (23.4%) with psoriatic arthritis (PsA), and 8 (2.0%) with juvenile idiopathic arthritis. Most of the cases of COVID-19 occurred in patients taking anti-TNF agents (84.2%), resulting in a significant disproportionality signal (ROR [95% CI]: 8.31 [7.48-9.23]) - particularly in patients with RA, AS or PsA. A significant inverse disproportionality was found for the anti-IL-6 agent tocilizumab (ROR [95% CI]: 0.12 [0.02-0.88]) and JAK inhibitors (ROR [95% CI]: 0.33 [0.19-0.58]) in patients with RA - suggesting that these two drug classes are safer in the context of RA. CONCLUSION: Our results are in line with the literature on a potentially better safety profile for anti-IL-6 agents and JAK inhibitors. The WHO pharmacovigilance data suggest that COVID-19 is significantly more frequent in patients with IRDs treated with TNF inhibitors. |
|---|
| 投稿日 | 2021/5/12 |
|---|
| 投稿者 | Dernoncourt, Amandine; Schmidt, Jean; Duhaut, Pierre; Liabeuf, Sophie; Gras-Champel, Valerie; Masmoudi, Kamel; Bennis, Youssef; Batteux, Benjamin |
|---|
| ジャーナル名 | Fundamental & clinical pharmacology |
|---|
| 組織名 | Department of Internal Medicine, Amiens-Picardie University Medical Center,;Amiens, France.;RECIF, Amiens-Picardie University Medical Center, Amiens, France.;Department of Clinical Pharmacology, Amiens University Medical Center, Amiens,;France.;MP3CV Laboratory, Jules Verne University of Picardie, Amiens, France.;Department of Rheumatology, Saint-Quentin Medical Center, Saint-Quentin, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33973280/ |
|---|
